(Q35823552)

10 August 2017

1 reference

title

Teriparatide (biosynthetic human parathyroid hormone 1-34): a new paradigm in the treatment of osteoporosis (English)

1 reference

10 August 2017

0 references

Kim T Brixen

1

1 reference

10 August 2017

Palle Mark Christensen

series ordinal

2

1 reference

10 August 2017

Charlotte Ejersted

series ordinal

3

1 reference

10 August 2017

Bente Lomholt Langdahl

series ordinal

4

1 reference

10 August 2017

publication date

1 June 2004

1 reference

Basic and Clinical Pharmacology and Toxicology

10 August 2017

published in

1 reference

10 August 2017

volume

94

1 reference

10 August 2017

issue

6

1 reference

10 August 2017

page(s)

260-270

1 reference

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

10 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2004.PTO940602.X

A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2004.PTO940602.X

Receptors for the carboxyl-terminal region of pth(1-84) are highly expressed in osteocytic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2004.PTO940602.X

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2004.PTO940602.X

The Effects of Parathyroid Hormone, Alendronate, or Both in Men with Osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2004.PTO940602.X

Developments in parathyroid hormone and related peptides as bone-formation agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2004.PTO940602.X

Fluoride for the treatment of postmenopausal osteoporotic fractures: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2004.PTO940602.X

Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2004.PTO940602.X

The parathyroid hormone (PTH)/PTH-related peptide receptor mediates actions of both ligands in murine bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2004.PTO940602.X

Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2004.PTO940602.X

Treatment of postmenopausal osteoporosis with transdermal estrogen

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2004.PTO940602.X

Effects of human parathyroid hormone (1-34), LY333334, on bone mass, remodeling, and mechanical properties of cortical bone during the first remodeling cycle in rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2004.PTO940602.X

Hormonal replacement therapy reduces forearm fracture incidence in recent postmenopausal women - results of the Danish Osteoporosis Prevention Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2004.PTO940602.X

The effect on vertebral bone mass and strength of long term treatment with antiresorptive agents (estrogen and calcitonin), human parathyroid hormone-(1-38), and combination therapy, assessed in aged ovariectomized rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2004.PTO940602.X

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2004.PTO940602.X

Colles' fracture of the wrist as an indicator of underlying osteoporosis in postmenopausal women: a prospective study of bone mineral density and bone turnover rate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2004.PTO940602.X

Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2004.PTO940602.X

Daily treatment with parathyroid hormone is associated with an increase in vertebral cross-sectional area in postmenopausal women with glucocorticoid-induced osteoporosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2004.PTO940602.X

Alendronate increases degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic women

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2004.PTO940602.X

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2004.PTO940602.X

Three-dimensional modeling of the effects of parathyroid hormone on bone distribution in lumbar vertebrae of ovariectomized cynomolgus macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2004.PTO940602.X

Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2004.PTO940602.X

Small bone-building fragments of parathyroid hormone: new therapeutic agents for osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2004.PTO940602.X

10.1111/J.1742-7843.2004.PTO940602.X

21 January 2018

Identifiers

DOI

0 references

1 reference